Labcorp is raising its 2026 guidance, buoyed by demand across its diagnostics and central laboratory businesses.
Sales for the first quarter totaled $3.54 billion, up 5.8% year over year. Growth was driven largely by the company’s Diagnostics segment, which rose 5% to $2.76 billion, while Biopharma Laboratory Services increased 8.2% to $780.6 million. Growth in the latter was primarily driven by central laboratory services within the segment, the company said.
Labcorp now expects full-year 2026 revenue of $14.65 billion to $14.80 billion, up from its prior forecast of $14.61 billion to $14.79 billion.
“Labcorp delivered another quarter of strong results, with robust growth and double-digit adjusted EPS growth driven by continued momentum across our Diagnostics and central laboratory businesses,” Chairman and CEO Adam Schechter said in the April 30 earnings release.
“Driven by continued progress across our strategic priorities, we are raising our full-year adjusted EPS guidance to $18.03 at the midpoint of the range, an increase of $0.13.”
Analysts from Evercore ISI said in a note to clients that Labcorp delivered a “’boring’ Q - in the best sense - with stable performance and improving fundamentals in Dx, the FY’26 guide of ~5.5% growth (midpoint) reflects a healthy mix of organic and M&A, with the majority organic.”
The firm added that: “Stepping back, despite the near-term noise (weather, ACA, fuel), we see core fundamentals with Diagnostics as solid, Early Development inflecting, and Central Labs continuing to perform, allowing solid visibility into at least the mid-to-high end of the ’26 EPS range.”